Sanjivani Paranteral shareholders have approved the preferential issuance of up to 5,00,000 convertible warrants to entities within the promoter group. The special resolution passed via postal ballot on August 24, 2026, with overwhelming support from eligible public investors.

The company also secured approval for material related-party transactions with its subsidiary, SPL Infusion Private Limited, under Regulation 23 of the SEBI (LODR) Regulations, 2015.

Voting Results

The postal ballot notice was issued on July 23, 2026, with a record date of July 17, 2026. As on the record date, the company had 5,143 shareholders. The total shareholding stood at 12,284,300 shares.

Promoters and the promoter group, holding 3,877,527 shares, abstained from voting due to their interest in the resolutions. Consequently, only public non-institutional shareholders participated in the e-voting process.

Both resolutions received 99.91% of the valid votes polled in their favour. Only 1,957 votes were cast against each resolution.

What the Numbers Show

The voting participation rate among public non-institutional shareholders was approximately 29.36%, calculated against their total shareholding of 7,795,907 shares. Despite this moderate participation rate, the near-unanimous support (99.91%) indicates strong alignment among active retail and non-institutional stakeholders regarding the capital structure changes and related-party approvals.

Sanjivani Paranteral Limited reported a 32.6% year-on-year increase in standalone net profit to ₹229.54 lakh for the quarter ended June 30, 2026. Revenue from operations rose 8.7% to ₹1,945.84 lakh, reflecting steady demand in the pharmaceutical segment.

The Mumbai-based manufacturer also posted consolidated net profit attributable to owners of ₹241.28 lakh, up 39.1% from ₹173.06 lakh in the same period last year. Consolidated revenue from operations expanded 33.2% to ₹2,383.92 lakh.

Financial Performance

The company’s earnings per share (EPS) increased to ₹1.87 from ₹1.46 in Q1FY25. Profit before tax stood at ₹306.05 lakh, compared to ₹230.06 lakh in the prior year quarter.

Consolidated figures showed stronger top-line momentum, with revenue reaching ₹2,383.92 lakh against ₹1,789.22 lakh in Q1FY25. Other income contributed ₹15.08 lakh to total revenue.

What the Numbers Show

A notable divergence exists between standalone and consolidated performance. While standalone revenue grew modestly at 8.7%, consolidated revenue surged 33.2%. This suggests that the subsidiary, SPL Infusion Pvt. Ltd., contributed significantly to the group’s top-line expansion during the quarter.

Corporate Actions

The Board of Directors approved the unaudited financial results along with the limited review report from statutory auditors R.B. Gohil & Co. The board also approved the Annual Report and Director’s Report for FY26.

Key corporate developments include:

• Notice convening the 32nd Annual General Meeting (AGM) on September 16, 2026, via video conferencing or other audio-visual means.
• Closure of register of members and share transfer books from September 10 to September 16, 2026.
• Appointment of HD & Associates as scrutinizer for remote e-voting.

The company received no investor complaints during the quarter. Statutory auditors expressed an unmodified opinion on the standalone results.